Autonomix reports results from first 15 patients’ data on transvascular energy

Autonomix (AMIX) Medical announced preliminary positive results from the first 15 patients in the Company’s ongoing proof-of-concept human clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain. Summary of First 15 Patients’ Topline Results 7-Days Post-Procedure: 11 patients were treated with femoral access and three) were treated with brachial access. Patients treated with brachial access showed no improvement in their pain scores while patients treated with femoral access did respond to treatment. 79% of patients responded with a mean 4.96 reduction of pain on the VAS pain scale at 7 days post-procedure. Study through 7 days post-procedure showed a decrease in opioid demand and no responding patient needed dose increase; No responding patient needed opioids after their 24-hour post-procedure follow-up visit. Responding patients reported a mean 66% improvement in overall health status at 7 days post-procedure.